Vascular Biogenics Stock Price, News & Analysis (NASDAQ:VBLT)

$6.85 -2.15 (-23.89 %)
(As of 11/20/2017 10:07 AM ET)
Previous Close$9.00
Today's Range$6.80 - $7.70
52-Week Range$3.90 - $9.05
Volume3.07 million shs
Average Volume153,371 shs
Market Capitalization$191.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.1

About Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:VBLT
  • Previous Symbol: NASDAQ:VBLX
  • CUSIP: N/A
  • Web: www.vblrx.com
Debt:
  • Current Ratio: 5.87%
  • Quick Ratio: 5.87%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.58 per share
  • Price / Book: 4.34
Profitability:
  • Trailing EPS: ($0.79)
  • Net Income: ($16,000,000.00)
  • Return on Equity: -58.36%
  • Return on Assets: -51.16%
Misc:
  • Employees: 34
  • Outstanding Shares: 27,120,000
 

Frequently Asked Questions for Vascular Biogenics (NASDAQ:VBLT)

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its earnings results on Monday, August, 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.09. View Vascular Biogenics' Earnings History.

When will Vascular Biogenics make its next earnings announcement?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Vascular Biogenics.

Where is Vascular Biogenics' stock going? Where will Vascular Biogenics' stock price be in 2017?

4 brokers have issued 1-year price objectives for Vascular Biogenics' stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Vascular Biogenics' share price to reach $16.00 in the next year. View Analyst Ratings for Vascular Biogenics.

What are Wall Street analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:

  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (10/18/2017)
  • 2. Piper Jaffray Companies analysts commented, "At the previous Nov '16 update, the study achieved its primary endpoint of 6-month PFS at therapeutic doses, as well as an intriguing overall survival benefit. However, today's update demonstrates a PFS-6 benefit of 47% vs 25% for therapeutic versus sub-therapeutic doses of VB-111, and confirmed a survival benefit, with mOS at 684 days in the therapeutic cohort. We see these results as meaningful in patients who had progressed on prior therapies including TKi's, and the safety and efficacy profile in this third tumor type reduces risk for VB-111 and the broader platform. That said, we don't expect VBL to pursue a Phase IIb/III trial in thyroid at this time, in favor of focusing on ongoing rGBM and soon-to-be-initiated ovarian cancer studies. In advance of clinical updates from those during 2017, we reiterate OW." (2/21/2017)

Who are some of Vascular Biogenics' key competitors?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:

  • Dror Harats M.D., Chief Executive Officer, Founder, Director (Age 57)
  • Amos Ron, Chief Financial Officer (Age 59)
  • Jacob George M.D., Chief Scientific Officer (Age 49)
  • Eyal Breitbart Ph.D., Vice President - Research and Operations (Age 47)
  • Erez Feige, Vice President - Business Operations (Age 40)
  • Yael Cohen M.D., Vice President - Clinical Development (Age 51)
  • Naamit Sher Ph.D., Vice President - Drug Development and Regulatory Affairs (Age 60)
  • Ayelet Horn, General Counsel, Company Secretary (Age 43)
  • Bennett M. Shapiro M.D., Non-Executive Independent Chairman of the Board (Age 76)
  • Ruth Alon, Non-Executive Director, Independent Director (Age 65)

Who owns Vascular Biogenics stock?

Vascular Biogenics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include First Eagle Investment Management LLC (1.01%), Migdal Insurance & Financial Holdings Ltd. (0.68%) and Zurcher Kantonalbank Zurich Cantonalbank (0.08%). View Institutional Ownership Trends for Vascular Biogenics.

Who sold Vascular Biogenics stock? Who is selling Vascular Biogenics stock?

Vascular Biogenics' stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC and Migdal Insurance & Financial Holdings Ltd.. View Insider Buying and Selling for Vascular Biogenics.

Who bought Vascular Biogenics stock? Who is buying Vascular Biogenics stock?

Vascular Biogenics' stock was purchased by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Vascular Biogenics.

How do I buy Vascular Biogenics stock?

Shares of Vascular Biogenics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of Vascular Biogenics stock can currently be purchased for approximately $6.85.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $191.17 million. The biopharmaceutical company earns ($16,000,000.00) in net income (profit) each year or ($0.79) on an earnings per share basis. Vascular Biogenics employs 34 workers across the globe.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 6 Jonathan Netanyahu St., OR YEHUDA, 6037604, Israel. The biopharmaceutical company can be reached via phone at +972-3-6346450 or via email at [email protected]


MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  253
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Vascular Biogenics (NASDAQ:VBLT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (133.58% upside)

Consensus Price Target History for Vascular Biogenics (NASDAQ:VBLT)

Price Target History for Vascular Biogenics (NASDAQ:VBLT)

Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017HC WainwrightReiterated RatingBuy$11.00N/AView Rating Details
11/6/2017Chardan CapitalBoost Price TargetBuy -> Buy$20.00 -> $25.00N/AView Rating Details
2/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$11.00N/AView Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Vascular Biogenics (NASDAQ:VBLT)

Earnings by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Earnings History by Quarter for Vascular Biogenics (NASDAQ VBLT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018        
8/14/20176/30/2017($0.19)($0.18)ViewN/AView Earnings Details
5/15/20173/31/2017($0.17)($0.19)ViewN/AView Earnings Details
3/27/201712/31/2016($0.19)($0.18)ViewListenView Earnings Details
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Vascular Biogenics (NASDAQ VBLT)

Source:
DateHeadline
Why Vascular Biogenics Ltd. Is Tanking Today - Motley FoolWhy Vascular Biogenics Ltd. Is Tanking Today - Motley Fool
www.fool.com - November 18 at 9:59 AM
Why Vascular Biogenics Ltd. Is Tanking TodayWhy Vascular Biogenics Ltd. Is Tanking Today
www.fool.com - November 17 at 12:56 PM
Vascular Biogenics Ltd (VBLT) PT Raised to $10 at JMP Securities - StreetInsider.comVascular Biogenics Ltd (VBLT) PT Raised to $10 at JMP Securities - StreetInsider.com
www.streetinsider.com - November 16 at 5:24 AM
Vascular Biogenics Ltd. to Host Earnings CallVascular Biogenics Ltd. to Host Earnings Call
finance.yahoo.com - November 16 at 5:24 AM
VBL Therapeutics Announces Third Quarter 2017 Financial ResultsVBL Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 16 at 5:24 AM
Vascular Biogenics reports 3Q lossVascular Biogenics reports 3Q loss
finance.yahoo.com - November 16 at 5:24 AM
Edited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMTEdited Transcript of VBLT earnings conference call or presentation 14-Nov-17 1:30pm GMT
finance.yahoo.com - November 16 at 5:24 AM
Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)?Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)?
finance.yahoo.com - November 13 at 8:23 PM
VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18
finance.yahoo.com - November 9 at 9:23 AM
BRIEF-VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in JapanBRIEF-VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan
www.reuters.com - November 7 at 11:26 PM
BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in JapanBRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
www.businessinsider.com - November 7 at 11:26 PM
Form 6-K Vascular Biogenics Ltd. For: Nov 06 - StreetInsider.comForm 6-K Vascular Biogenics Ltd. For: Nov 06 - StreetInsider.com
www.streetinsider.com - November 7 at 1:00 PM
Vascular Biogenics Ltd (VBLT) PT Raised to $25 at Chardan Capital Markets - StreetInsider.comVascular Biogenics Ltd (VBLT) PT Raised to $25 at Chardan Capital Markets - StreetInsider.com
www.streetinsider.com - November 7 at 1:00 PM
VBL Therapeutics to Report Third Quarter 2017 Results on November 14VBL Therapeutics to Report Third Quarter 2017 Results on November 14
finance.yahoo.com - November 7 at 12:59 PM
Vascular Biogenics Ltd. (VBLT) Expected to Announce Earnings of -$0.18 Per ShareVascular Biogenics Ltd. (VBLT) Expected to Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - November 6 at 1:20 PM
Vascular Biogenics Ltd. (VBLT) Given New $25.00 Price Target at Chardan CapitalVascular Biogenics Ltd. (VBLT) Given New $25.00 Price Target at Chardan Capital
www.americanbankingnews.com - November 6 at 11:38 AM
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan - GlobeNewswire (press release)VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan - GlobeNewswire (press release)
globenewswire.com - November 6 at 8:48 AM
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in JapanVBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan
finance.yahoo.com - November 6 at 8:48 AM
Vascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Buy" by BrokeragesVascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 4:02 PM
Critical Survey: Vascular Biogenics (VBLT) vs. Gemphire Therapeutics (GEMP)Critical Survey: Vascular Biogenics (VBLT) vs. Gemphire Therapeutics (GEMP)
www.americanbankingnews.com - November 4 at 11:40 PM
Vascular Biogenics Ltd. (VBLT) to Release Earnings on WednesdayVascular Biogenics Ltd. (VBLT) to Release Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Vascular Biogenics Stock May Shoot Up On The Back Of Upcoming Catalysts - Seeking AlphaVascular Biogenics Stock May Shoot Up On The Back Of Upcoming Catalysts - Seeking Alpha
seekingalpha.com - October 31 at 11:41 AM
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company HeadquartersVBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters
finance.yahoo.com - October 23 at 8:47 AM
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in EuropeVBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
finance.yahoo.com - October 20 at 9:47 AM
Vascular Biogenics Ltd. (VBLT) Receives Average Rating of "Hold" from BrokeragesVascular Biogenics Ltd. (VBLT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 4:42 PM
VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBMVBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
finance.yahoo.com - October 3 at 2:26 PM
VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBMVBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
finance.yahoo.com - October 3 at 2:26 PM
VBL Therapeutics to Present at the Chardan Gene Therapy ConferenceVBL Therapeutics to Present at the Chardan Gene Therapy Conference
www.nasdaq.com - September 28 at 8:54 AM
Vascular Biogenics (VBLT) versus Its Competitors Head to Head AnalysisVascular Biogenics (VBLT) versus Its Competitors Head to Head Analysis
www.americanbankingnews.com - September 27 at 4:32 PM
Vascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Hold" by BrokeragesVascular Biogenics Ltd. (VBLT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 4:36 PM
VBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New YorkVBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York
finance.yahoo.com - September 15 at 10:59 AM
Vascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.18 Per ShareVascular Biogenics Ltd. (VBLT) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - September 10 at 6:34 AM
VBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017VBL Therapeutics to Present at the Rodman & Renshaw Global Investment Conference in New York on September 10-12, 2017
finance.yahoo.com - August 29 at 9:19 AM
Vascular Biogenics Ltd. (VBLT) Receives Consensus Rating of "Buy" from AnalystsVascular Biogenics Ltd. (VBLT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%
finance.yahoo.com - August 17 at 8:59 AM
Vascular Biogenics Ltd. (VBLT) PT Set at $11.00 by HC WainwrightVascular Biogenics Ltd. (VBLT) PT Set at $11.00 by HC Wainwright
www.americanbankingnews.com - August 15 at 6:40 PM
Vascular Biogenics (VBLT) CEO Dror Harats on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaVascular Biogenics' (VBLT) CEO Dror Harats on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 3:36 PM
Edited Transcript of VBLT earnings conference call or presentation 14-Aug-17 12:30pm GMTEdited Transcript of VBLT earnings conference call or presentation 14-Aug-17 12:30pm GMT
finance.yahoo.com - August 15 at 3:35 PM
Vascular Biogenics Ltd. (NASDAQ:VBLT) Posts  Earnings Results, Misses Estimates By $0.01 EPSVascular Biogenics Ltd. (NASDAQ:VBLT) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 14 at 11:30 AM
Earnings Scheduled For August 14, 2017 - BenzingaEarnings Scheduled For August 14, 2017 - Benzinga
www.benzinga.com - August 14 at 8:11 AM
VBL Therapeutics Announces Second Quarter 2017 Financial ResultsVBL Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 8:11 AM
Vascular Biogenics reports 2Q lossVascular Biogenics reports 2Q loss
finance.yahoo.com - August 14 at 8:11 AM
Vascular Biogenics Ltd. (VBLT) Scheduled to Post Earnings on MondayVascular Biogenics Ltd. (VBLT) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 7:08 AM
Head to Head Review: Vascular Biogenics (VBLT) vs. MEI Pharma (MEIP)Head to Head Review: Vascular Biogenics (VBLT) vs. MEI Pharma (MEIP)
www.americanbankingnews.com - August 4 at 10:16 PM
VBL Therapeutics to Report Second Quarter 2017 Results on August 14VBL Therapeutics to Report Second Quarter 2017 Results on August 14
finance.yahoo.com - August 2 at 8:23 AM
Vascular Biogenics Ltd. (NASDAQ:VBLT) Given Consensus Rating of "Buy" by AnalystsVascular Biogenics Ltd. (NASDAQ:VBLT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 4:39 PM
Vascular Biogenics is Now Oversold (VBLT)Vascular Biogenics is Now Oversold (VBLT)
www.thestreet.com - July 14 at 4:52 PM
-$0.17 EPS Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter-$0.17 EPS Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter
www.americanbankingnews.com - July 13 at 7:54 AM
Vascular Biogenics Ltd. (VBLT) Given Average Recommendation of "Buy" by BrokeragesVascular Biogenics Ltd. (VBLT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 4:58 PM
Vascular Biogenics: An Under-The-Radar Oncology Play Near $6 - Seeking AlphaVascular Biogenics: An Under-The-Radar Oncology Play Near $6 - Seeking Alpha
seekingalpha.com - May 26 at 8:19 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Vascular Biogenics (NASDAQ VBLT) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.